The latest price target for HOOKIPA Pharma (NASDAQ:HOOK) was reported by JMP Securities on August 9, 2024. The analyst firm set a price target for $24.00 expecting HOOK to rise to within 12 months (a possible 409.55% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for HOOKIPA Pharma (NASDAQ:HOOK) was provided by JMP Securities, and HOOKIPA Pharma maintained their market outperform rating.

There is no last upgrade for HOOKIPA Pharma

The last downgrade for HOOKIPA Pharma Inc happened on December 2, 2022 when B of A Securities changed their price target from $6 to $0.5 for HOOKIPA Pharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HOOKIPA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HOOKIPA Pharma was filed on August 9, 2024 so you should expect the next rating to be made available sometime around August 9, 2025.

While ratings are subjective and will change, the latest HOOKIPA Pharma (HOOK) rating was a maintained with a price target of $23.00 to $24.00. The current price HOOKIPA Pharma (HOOK) is trading at is $4.71, which is out of the analyst’s predicted range.